Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- HAEMATOLOGICA103(12) · pp.2079 · 2018
- 피인용
- Web of Science 232Scopus 248
- FWCI (Scopus)
- 10.29
- JCR IF
- JCR 2017 9.09
- ISSN
- 0390-6078
저자
- Spencer, Andrew제1저자교신저자Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia
- Lentzsch, SuzanneDivision of Hematology/Oncology, Columbia University, New York, United States
- Weisel, KatjaUniversitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II, Tübingen, Germany
- Avet-Loiseau, HervéUnite de Genomique du Myelome, CHU Rangueil, Toulouse, France
- Mark, Tomer M.Department of Medicine, University of Colorado, Aurora, United States
- Spicka, IvanClinical Department of Haematology, 1st Medical Department, Charles University in Prague, Czech Republic
- Masszi, TamasDepartment of Haematology and Stem Cell Transplantation, St László Hospital, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
- Lauri, BirgittaDepartment of Hematology, Sunderbyn Hospital, Luleå, Sweden
- Levin, Mark-DavidAlbert Schweitzer Hospital Department of Internal Medicine, Dordrecht, Netherlands
- Bosi, AlbertoDepartment of Hematology, Careggi Hospital and University of Florence, Italy
- Hungria, VaniaIrmandade Da Santa Casa De Misericordia De São Paulo, Brazil
- Cavo, Michele“Seràgnoli” Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy
- Lee, Je-JungDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Jeollanamdo, South Korea
- Nooka, Ajay K.Winship Cancer Institute, Emory University, Atlanta, United States
- Quach, HangSt. Vincent's Hospital, University of Melbourne, Australia
- Lee, CindyRoyal Adelaide Hospital, Australia
- Barreto, WolneyHospital Santa Marcelina, São Paulo, Brazil
- Corradini, PaoloFondazione IRCCS Instituto Nazionale dei Tumori, University of Milan, Italy
- Min, Chang-KiSeoul St. Mary’s Hospital, South Korea
- Scott, Emma C.Oregon Health & Science University, Portland, United States
- Chanan-Khan, Asher A.Mayo Clinic Florida, Jacksonville, United States
- Horvath, NoemiRoyal Adelaide Hospital, Australia
- Capra, MarceloInstituto do Cancer-Hospital Mae de Deus, Porto Alegre, Brazil
- Beksac, MeralAnkara University, Turkey
- Ovilla, RobertoHospital Angeles Lomas, Naucalpan de Juárez y alrededores, Mexico
- Jo, Jae-CheolUlsan University Hospital, South Korea
- 신호진Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, Busan, South Korea
- Sonneveld, PieterErasmus Medical Center, Rotterdam, Netherlands
- Soong, DavidJanssen Research & Development, LLC, United States
- Casneuf, TinekeJanssen Research & Development, Beerse, Belgium
초록
Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or refractory multiple myeloma. A post hoc analysis based on treatment history and longer follow-up is presented. After 19.4 (range: 0 to 27.7) months of median follow-up, daratumumab plus bortezomib and dexamethasone prolonged progression-free survival (median: 16.7 versus 7.1 months; hazard ratio, 0.31; 95% confidence interval, 0.24-0.39; P <0.0001) and improved the overall response rate (83.8% versus 63.2%; P <0.0001) compared with bortezomib and dexamethasone alone. The progression-free survival benefit of daratumumab plus bortezomib and dexamethasone was most apparent in patients with 1 prior line of therapy (median: not reached versus 7.9 months; hazard ratio, 0.19; 95% confidence interval, 0.12-0.29; P <0.0001). Daratumumab plus bortezomib and dexamethasone was also superior to bortezomib and dexamethasone alone in subgroups based on prior treatment exposure (bortezomib, thalidomide, or lenalidomide), lenalidomide-refractory status, time since last therapy (=12, >12, =6, or >6 months), or cytogenetic risk. Minimal residual disease-negative rates were >2.5-fold higher with daratumumab across subgroups. The safety profile of daratumumab plus bortezomib and dexamethasone remained consistent with longer follow-up. Daratumumab plus bortezomib and dexamethasone demonstrated significant clinical activity across clinically relevant subgroups and provided the greatest benefit to patients treated at first relapse. TRIAL EGISTRATION: clinicaltrials.gov identifier: NCT02136134.
키워드
MINIMAL RESIDUAL DISEASELOW-DOSE DEXAMETHASONEOPEN-LABELINTERGROUPE FRANCOPHONEANTIBODY DARATUMUMABTARGETING CD38LENALIDOMIDEPOMALIDOMIDESURVIVALTHERAPY
식별자
- Scopus EID
- 2-s2.0-85057954011
- WoS UID
- 000451736600033



로그인
연구물 목록으로